Cellulose Or Derivative Patents (Class 514/781)
  • Spray pack
    Patent number: 7094448
    Abstract: Disclosed is a spray pack for use in forming a uniform, stable spray coating, comprising a spray container device and, packed therein, a spraying composition comprising a liquid dispersion medium and, dispersed therein, particulate cellulose having an average degree of polymerization (DP) of not more than 300 and an average particle diameter of not more than 10 ?m, wherein the composition has a cellulose content of from 0.1 to 5.0% by weight, and wherein the composition exhibits a maximum viscosity value (?max) of 1×103 mPa·s or more in the viscosity-shear stress curve obtained, with respect to the composition, using a cone-plate type rotating viscometer in a shear rate region of from 1×10?3 s?1 to 1×102 s?1 and at 25° C. A method for forming a uniform, stable spray coating by using the above-mentioned spray pack is also disclosed.
    Type: Grant
    Filed: December 27, 2002
    Date of Patent: August 22, 2006
    Assignee: Asahi Kasei Chemical Corporation
    Inventors: Hirofumi Ono, Hideki Amakawa
  • Artemisinins with improved stability and bioavailability for therapeutic drug development and application
    Patent number: 7084132
    Abstract: A stable form of artemisinin wherein an artelinic acid or artesunic acid is complexed with cyclodextrin analogs, preferably, ?-cyclodextrin. The complexed cyclodextrin artemisinin formulation shields the peroxide portion of the artemisinin backbone from hydrolytic decomposition rendering it stable in solution. Artelinic acid and cyclodextrin are placed into contact with one another to yield a 2:1 molecular species. Artesunic acid and cyclodextrin yield a 1:1 molecular species. The complexed cyclodextrin artemisinin formulation is effective for the treatment of malaria and is stable in solution for long periods of time.
    Type: Grant
    Filed: April 25, 2005
    Date of Patent: August 1, 2006
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Mark G. Hartell, Apurba K. Bhattacharjee, Rickey P. Hicks, John E. VanHamont, Wilbur K. Milhous
  • Method of treating hematologic tumors and cancers
    Patent number: 7070797
    Abstract: Multiple myeloma and other hematologic tumors and/or malignancies can be treated by administration of a G1 and/or S phase drug, which is preferably ?-lapachone, or a derivative or analog thereof, combined with a G2/M phase drug such as a taxane derivative, which is advantageously paclitaxel. This combination of the G1 and/or S phase drug with the G2/M phase drug results in an unexpectedly greater than additive (i.e., synergistic) apoptosis in multiple myeloma cells. The invention includes methods of treating multiple myeloma by administering the combination of the G1 and/or S phase drug and the G2/M phase drug, pharmaceutical compositions comprising the combination of drugs used in these methods, as well as pharmaceutical kits.
    Type: Grant
    Filed: July 31, 2002
    Date of Patent: July 4, 2006
    Assignee: Dana Farber Cancer Institute, Inc.
    Inventors: Arthur B. Pardee, Kenneth Anderson, Deepak Gupta, Chiang Li, Youzhi Li
  • Polymer controlled induced viscosity fiber system and uses thereof
    Patent number: 7067498
    Abstract: The present invention relates generally to a method of blunting the postprandial glycemic response in a human by feeding an induced viscosity fiber system. The invention also relates to an induced viscosity fiber system and the liquid products that incorporate the induced viscosity fiber system. Further, the invention relates to a method of incorporating soluble fiber into a liquid product without the typical negative organoleptic or physical stability issues. The invention also relates to a method of inducing the feeling of fullness and satiety by feeding the induced viscosity fiber system.
    Type: Grant
    Filed: May 29, 2002
    Date of Patent: June 27, 2006
    Assignee: Abbott Laboratories
    Inventors: Bryan W. Wolf, Bruce B. Blidner, Keith A. Garleb, Chron-Si Lai, Timothy W. Schenz
  • Pharmaceutical coating composition and method of use
    Patent number: 7060734
    Abstract: A composition is disclosed comprising a polymer and a surfactant in a solvent exhibiting a common solubility for the polymer and the surfactant. The composition provides a dosage form for administering a drug over time.
    Type: Grant
    Filed: November 22, 2000
    Date of Patent: June 13, 2006
    Assignee: Alza Corporation
    Inventors: David E. Edgren, Shu Li, Patrick S.-L. Wong, Gurdish Bhatti, Liang-Chang Dong, Si-Hong Yum
  • Antimycotic nail varnish composition
    Patent number: 7033578
    Abstract: The present invention relates to a composition comprising a) at least one antimycotic agent and b) at least one film forming agent wherein component b) is a derivative of chitosan selected from hydroxyalkylchitosans and carboxyalkylchitosans and its use as a nail varnish. The present invention is further directed to the use of a water soluble film forming agent selected from hydroxyalkylchitosans and carboxyalkylchitosans as an additive in a nail varnish.
    Type: Grant
    Filed: July 18, 2001
    Date of Patent: April 25, 2006
    Assignee: Polichem S.A.
    Inventor: Federico Mailland
  • Multiparticulate formulations of lithium salts for oral administration suitable for once-a-day administration
    Patent number: 6994873
    Abstract: This invention refers to: multiparticulate formulations of Lithium salts for oral administration constituted by either modified release granules or mixtures of modified and conventional release granules, suitable for once-a-day administration also at high strengths of Lithium salts, and to the preparation process of said formulations.
    Type: Grant
    Filed: February 4, 2002
    Date of Patent: February 7, 2006
    Assignee: Valpharma S.A.
    Inventors: Roberto Valducci, Tiziano Alighieri, Serozh Avanessian
  • Compositions for treating hyperemia
    Patent number: 6982079
    Abstract: The present compositions advantageously treat hyperemia with substantially no added irritation to the eye. In one embodiment, the compositions include an ophthalmically acceptable carrier component, a vasoconstrictor component in an amount effective to treat hyperemia when the composition is administered to an eye, and a polyanionic component in an amount effective to provide lubrication to an eye when the compositions are administered to the eye.
    Type: Grant
    Filed: April 26, 2002
    Date of Patent: January 3, 2006
    Assignee: Allergan, Inc.
    Inventor: Stanley W. Huth
  • Method for producing a controlled-release preparation
    Patent number: 6974591
    Abstract: The invention concerns a method for producing a controlled-release pharmaceutical preparation with a particle-containing coating, the coating being derived from an aqueous dispersion of a film-forming water insoluble polymer and a water soluble pore-forming agent. By suspending, instead of dissolving the pore-forming agent, the resulting coating will contain particles of the pore-formers with a predetermined size that creates, when disintegrated or dissolved in the body fluid, canals or a network of pores through the polymer film. Due to this network, the film will get a good mechanical stability and are left intact after the release of the drug.
    Type: Grant
    Filed: March 29, 2001
    Date of Patent: December 13, 2005
    Assignee: Watson Laboratories, Inc.
    Inventors: John Kendrup, Peter Fyhr
  • Pharmaceutical gel composition
    Patent number: 6958159
    Abstract: The present invention relates to an improved pharmaceutical composition useful for the topical treatment of burns, cuts, wounds, abrasions and the like, and to methods of treatment of injured body surfaces such as skin.
    Type: Grant
    Filed: March 26, 2001
    Date of Patent: October 25, 2005
    Assignee: Chiltern Pharmaceuticals, Pty Ltd.
    Inventor: Robert Alan Smith
  • Artemisinins with improved stability and bioavailability for therapeutic drug development and application
    Patent number: 6951846
    Abstract: A stable form of artemisinin wherein an artelinic acid or artesunic acid is complexed with cyclodextrin analogs, preferably, ?-cyclodextrin. The complexed cyclodextrin artemisinin formulation shields the peroxide portion of the artemisinin backbone from hydrolytic decomposition rendering it stable in solution. Artelinic acid and cyclodextrin are placed into contact with one another to yield a 2:1 molecular species. Artesunic acid and cyclodextrin yield a 1:1 molecular species. The complexed cyclodextrin artemisinin formulation is effective for the treatment of malaria and is stable in solution for long periods of time.
    Type: Grant
    Filed: February 27, 2003
    Date of Patent: October 4, 2005
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Mark G. Hartell, Apurba K. Bhattacharjee, Rickey P. Hicks, John E. VanHamont, Wilbur K. Milhous
  • Amino acid modulated extended release dosage form
    Patent number: 6936275
    Abstract: Disclosed herein is a oral extended release dosage form comprising a plurality of granules of an effective amount of a pharmaceutically active compound, at least one amino acid, and an intragranular polymer in which the granule is dispersed within a hydrophilic extragranular polymer matrix which is more rapidly hydrating than the intragranular polymer. The amino acid is selected for hydropathy characteristics depending on solubility characteristics of the active compound.
    Type: Grant
    Filed: February 11, 2003
    Date of Patent: August 30, 2005
    Assignee: Scolr, Inc.
    Inventors: A. Reza Fassihi, Thomas Dürig
  • Vitamin formulation for cardiovascular health
    Patent number: 6914073
    Abstract: The invention concerns a composition containing a high level of Vitamin E in encapsulated form, preferably as beadlets or spray dried, and a high level of silicates. The composition is compressible into tablets or caplets that do not leach out Vitamin E into the tablet matrix during compression and/or storage. The composition preferably contains vitamins and minerals in doses optimized for cardiovascular health.
    Type: Grant
    Filed: January 14, 2002
    Date of Patent: July 5, 2005
    Assignee: Bristol Myers Squibb Company
    Inventors: Atef Boulos, Jatin Desai, Neil Martin, Robert Stillman, Marion Udwin
  • Penetrating antibiotic gel for soft tissue diseases
    Patent number: 6914051
    Abstract: A penetrating antibiotic gel for treating pain, inflammation and other pathological conditions affecting musculoskeletal tissues and other soft tissues of the body. The composition includes an antibiotic compound and a mobilizing agent in an amount sufficient to enable the antimicrobial compound to penetrate into the sub-dermal soft tissues. The antimicrobial compound may be a macrolide antibiotic compound such as azithromycin, erythromycin or roxithromycin, for example, and the mobilizing agent may be an organogel compound, such as pluronic lecithin liposomal organogel (PLO). The composition may further include a penetration enhancing adjuvant, such as d-limonene, for example. The composition may be applied topically so as to penetrate into the sub-dermal soft tissues, or may injected so as to be absorbed into the soft tissues locally.
    Type: Grant
    Filed: June 28, 2001
    Date of Patent: July 5, 2005
    Inventor: David M Allen
  • Hydrogel-driven layered drug dosage form
    Patent number: 6899896
    Abstract: A controlled release dosage form for sertraline has a core comprising a sertraline-containing composition and a water-swellable composition wherein the water-swellable composition is in a separate region within the core. A coating around the core is water-permeable, water-insoluble, and has at least one delivery port therethrough. In one embodiment, the dosage form releases sertraline to the use environment at an average rate of 6 to 10 wt % per hour from the second to the twenth hour after introduction to a use environment and less than about 25 wt % for the first two hours and at least 70 wt % by the twelfth hour, where the percentages correspond to the mass of drug released from the tablet divided by the total mass of drug originally present in the tablet.
    Type: Grant
    Filed: December 20, 2000
    Date of Patent: May 31, 2005
    Assignee: Pfizer Inc
    Inventors: William J. Curatolo, Kenneth C. Waterman, Avinash G. Thombre, Michael B. Fergione, Michael C. Roy, Leah A. Appel, Danni Supplee, Dwayne T. Friesen, Mark B. Chidlaw, Ronald A. Beyerinck
  • Stable pharmaceutical compositions without a stabilizer
    Patent number: 6893660
    Abstract: Stabilized controlled release pharmaceutical preparations are disclosed in which active ingredient degradation is prevented without the use of a stabilizer. The active ingredient is sealed away from excipients that can adversely affect stability by sealing the excipients rather than the active ingredient. The preparations are substantially unaffected by exposure to storage conditions of elevated temperature and/or elevated relative humidity.
    Type: Grant
    Filed: November 21, 2002
    Date of Patent: May 17, 2005
    Assignee: Andrx Pharmaceuticals, Inc.
    Inventors: Boyong Li, Xiu Xiu Cheng
  • Compositions of polyacids and polyethers and methods for their use in reducing adhesions
    Patent number: 6869938
    Abstract: The present invention relates to improved methods for making and using bioadhesive, bioresorbable, anti-adhesion compositions made of intermacromolecular complexes of carboxyl-containing polysaccharides, polyethers, polyacids, polyalkylene oxides, multivalent cations and/or polycations. The polymers are associated with each other, and are then either dried into membranes or sponges, or are used as fluids or microspheres. Bioresorbable, bioadhesive, anti-adhesion compositions are useful in surgery to prevent the formation and reformation of post-surgical adhesions. The compositions are designed to breakdown in-vivo, and thus be removed from the body. Membranes are inserted during surgery either dry or optionally after conditioning in aqueous solutions.
    Type: Grant
    Filed: December 27, 1999
    Date of Patent: March 22, 2005
    Assignee: FzioMed, Inc.
    Inventors: Herbert E. Schwartz, John M. Blackmore, Stephanie M. Cortese, William G. Oppelt
  • Controlled delivery of active agents
    Patent number: 6855334
    Abstract: Controlled release of active agents from sustained release push delivery devices having high drug loading are described wherein residual drug content in the device is minimized by the utilization of a flow-promoting layer between a semi-permeable wall and drug layer comprising the device.
    Type: Grant
    Filed: November 27, 2001
    Date of Patent: February 15, 2005
    Assignee: Alta Corporation
    Inventors: Padmanabh Bhatt, Evangeline Cruz, Noymi Yam
  • Calcium phosphate composition and method of preparing same
    Patent number: 6849275
    Abstract: A method for controlling the formation of a hydroxyapatite bone filler from dry calcium phosphate precursors in an aqueous solution uses coated sodium phosphate powder. The sodium phosphate powder is coated with a water soluble cellulose. Until the cellulose dissolves in the aqueous solution setting of the calcium phosphate cements proceeds slowly but when the exposed sodium phosphate particles start to solubilize in the aqueous solution the setting rate increases.
    Type: Grant
    Filed: January 10, 2003
    Date of Patent: February 1, 2005
    Assignee: Howmedica Osteonics Corp.
    Inventor: Paul Higham
  • Tablet composition
    Patent number: 6844008
    Abstract: A tablet composition containing N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine and a disintegrant, selected from a low substituted hydroxypropylcellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose and sodium croscaramellose sodium, is disclosed. This tablet composition is rapidly disintegrated in the stomach after the administration and absorbed without being influenced by meals to inhibit the rise of the blood sugar levels of diabetics after meals.
    Type: Grant
    Filed: February 5, 2003
    Date of Patent: January 18, 2005
    Assignee: Ajinomoto Co., Inc.
    Inventors: Akira Yabuki, Masato Kaida, Takahiko Ando, Nobutaka Ninomiya, Masanao Ozaki
  • Fenofibrate-cyclodextrin inclusion complexes and their pharmaceutical composition
    Patent number: 6828334
    Abstract: The present invention relates to pharmaceutical compositions containing fenofibrate in the form of an inclusion complex with cyclodextrin, having high dissolution profile and in vivo enhanced bioavailability as compared with plain micronized fenofibrate compositions. An inclusion complex has a molar ratio of fenofibrate (preferably in micronized form) to cyclodextrin of from about 1:0.5 to about 1:4, preferably from about 1:1 to about 1:2. The immediate release fenofibrate composition is preferably in the form of a tablet or in the form of granules inside a capsule.
    Type: Grant
    Filed: January 7, 2003
    Date of Patent: December 7, 2004
    Assignee: USV Limited
    Inventors: Suresh Kumar Gidwani, Purushottam Sharshikant Singnurkar
  • Process for preparing a soft tablet
    Patent number: 6814978
    Abstract: The invention relates to a process for preparing a soft tablet capable of being chewed or disintegrated in the oral cavity. The tablet is prepared by forming a tablet having a friability of less than about 2% from a mixture comprising a pharmaceutically active ingredient, an excipient in the form of a hydrate, and a water-swellable excipient, and then applying sufficient energy, preferably in the form of heat, to the tablet for a sufficient time to decrease the hardness of the tablet by at least about 20%.
    Type: Grant
    Filed: December 29, 2000
    Date of Patent: November 9, 2004
    Assignee: McNeil-PPC, Inc.
    Inventors: Frank J. Bunick, Joseph Luber
  • Bleeding control and healing aid compositions and methods of use
    Patent number: 6797260
    Abstract: A composition is disclosed which has been shown to stop or control bleeding and seal open small blood vessels while accelerating the healing process of abraded oral “gum” and other “skin” (epithelial) tissues. The composition is preferably in the form of a paste which promotes ease of application and use of the composition. A variety of instruments can be used in application and cleanup of the composition showing versatile unparalleled friendly usage. The composition preferably comprises aluminum chloride, ferric sulfate (subsulfate), regenerated oxidized cellulose, aluminum ammonium sulfate, absorbable gelatin and a solvent. The composition has many dental and medical procedure applications.
    Type: Grant
    Filed: September 18, 2003
    Date of Patent: September 28, 2004
    Inventor: Terence Prevendar
  • Encapsulation compositions and process for preparing the same
    Patent number: 6790453
    Abstract: Encapsulation compositions in which an encapsulate (A) is encapsulated in a matrix (B) may be prepared by: (i) mixing matrix (B) with a liquid plasticizer and encapsulate (A) in an extruder, to obtain a melted mixture of encapsulate (A) and matrix (B); and (ii) extruding the melted mixture, to obtain an extruded mixture.
    Type: Grant
    Filed: March 14, 2002
    Date of Patent: September 14, 2004
    Assignee: McCormick & Company, Inc.
    Inventors: Michael A. Porzio, Dmitriy Zasypkin
  • Oral 2-methyl-thieno-benzodiazepine formulation
    Patent number: 6780433
    Abstract: The invention provides a pharmaceutically elegant solid oral formulation of olanzapine and a process for making such formulation.
    Type: Grant
    Filed: January 19, 2001
    Date of Patent: August 24, 2004
    Assignee: Eli Lilly and Company
    Inventors: George Randall Cochran, Tommy Clifford Morris
  • Clear oil-containing pharmaceutical compositions containing a therapeutic agent
    Patent number: 6761903
    Abstract: The present invention relates to pharmaceutical compositions and methods for improved solubilization of triglycerides and improved delivery of therapeutic agents. Compositions of the present invention include a carrier, where the carrier is formed from a combination of a triglyceride and at least two surfactants, at least one of which is hydrophilic. Upon dilution with an aqueous medium, the carrier forms a clear, aqueous dispersion of the triglyceride and surfactants.
    Type: Grant
    Filed: June 8, 2001
    Date of Patent: July 13, 2004
    Assignee: Lipocine, Inc.
    Inventors: Feng-Jing Chen, Mahesh V. Patel, David T. Fikstad
  • Process for the preparation of direct tabletting formulations and aids
    Patent number: 6761905
    Abstract: A thermal adhesion granulation process for preparing direct tabletting formulations or aids is disclosed. The process comprises the step of subjecting all or part of a mixture comprising: A) from about 5 to about 99% by weight of one or more diluent excipients and/or from 0 to about 99% by weight of a pharmaceutically active ingredient; B) from about 1 to about 95% by weight of a binder excipient; optionally with, C) from 0 to about 10% by weight of a disintegrant excipient; to heating at a temperature in the range of from about 30 to about 130° C. under the condition of low moisture or low content of a pharmaceutically-acceptable organic solvent in a closed system under mixing by tumble rotation until the formation of granules.
    Type: Grant
    Filed: May 1, 2001
    Date of Patent: July 13, 2004
    Assignee: Wei Ming Pharmaceutical Mfg. Co., Ltd.
    Inventors: Ta-Shuong Yeh, Daniel Hungting Yeh
  • Burst-release polymer composition and dosage forms comprising the same
    Publication number: 20040129174
    Abstract: A composition comprising a high molecular weight, water soluble polymer having a cloud point from about 20 to about 90° C. and at least one carrageenan is provided. The composition may be used as a component of a pharmaceutical dosage form, such as the shell of a dosage form, to provide burst release of active ingredient contained therein.
    Type: Application
    Filed: October 28, 2003
    Publication date: July 8, 2004
    Inventors: Shun-Por Li, Der-Yang Lee, Frank J. Bunick, Jen Chi Chen, Harry S. Sowden
  • Combined diffusion/osmotic pumping drug delivery system
    Patent number: 6753011
    Abstract: Delivery devices capable of delivering one or more active substances by diffusion through plural micropores in the membrane (4) or by osmotic pumping through one or more preformed passageways (5) in the membrane are provided. The device (1) has an about centrally located expandable core (2) completely surrounded by an active substance-containing layer (3), which is completely surrounded by the membrane. The device is capable of delivering insoluble, slightly soluble, sparingly soluble and very soluble active substances to an environment of use. The preferred delivery rate is zero order. The device can deliver an active substance for a period of about 12-24 hours.
    Type: Grant
    Filed: January 15, 2002
    Date of Patent: June 22, 2004
    Assignee: Osmotica Corp
    Inventor: Joaquina Faour
  • Temperature controlled solute delivery system
    Patent number: 6733788
    Abstract: A system for delivering solute to a target location within a mammalian body, the system including a medical device, a thermosensitive cellulose gel structure over the medical device, and a biologically active solute within said gel structure. The gel structure deswells and expels the biologically active solute with an increase in gel temperature. The invention includes a method of delivering solute to a target location, where the method includes the steps of providing a thermosensitive cellulose gel structure, wherein the gel structure is loaded with a solute; positioning the loaded gel structure to the target location; and increasing the temperature of the loaded gel structure.
    Type: Grant
    Filed: May 23, 2000
    Date of Patent: May 11, 2004
    Assignee: SciMed Life Systems, Inc.
    Inventors: James F. McBride, Stevin H. Gehrke, John P. Fisher
  • Use of crosslinked polymers as anti-leaching agents
    Patent number: 6727204
    Abstract: The invention concerns the use, in an aqueous spray mixture comprising a phytosanitary formulation, of an anti-leaching agent comprising: at least a polyhydroxyl and/or polycarboxyl polymer or copolymer; at least a crosslinking agent comprising a metal selected among columns IVA, IB and IIIB of the periodic table; said anti-leaching agent being, in the aqueous spray mixture, in the form of an aqueous solution or dispersion having a polymer or copolymer concentration such that the viscosity of the anti-leaching agent is not more than 10 times the viscosity of the aqueous solution in polymer or copolymer without crosslinking agent, having the same concentration.
    Type: Grant
    Filed: January 7, 2002
    Date of Patent: April 27, 2004
    Assignee: Rhodia Chimie
    Inventors: Vance Bergeron, Cécile Bonnet-Gonnet, Jean-Christophe Castaing, Giles Guerin
  • Melt-extrusion multiparticulates
    Patent number: 6706281
    Abstract: A unit dose sustained-release oral dosage form containing a plurality of melt-extruded particles, each consisting essentially of a therapeutically active agent, one or more retardants, and an optional water-insoluble binder is disclosed. The particles have a length of from about 0.1 to about 12 mm and can be of varying diameters and each unit dose provides a release of therapeutically active agents over at least about 8 hours. Methods of preparing the unit doses as well as extrusion processes and methods of treatment are also disclosed.
    Type: Grant
    Filed: January 2, 2002
    Date of Patent: March 16, 2004
    Assignee: Euro-Celtique, S.A.
    Inventors: Benjamin Oshlack, Mark Chasin, Hua-Pin Huang
  • Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
    Patent number: 6699493
    Abstract: Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.
    Type: Grant
    Filed: November 28, 2001
    Date of Patent: March 2, 2004
    Assignee: Oculex Pharmaceuticals, Inc.
    Inventor: Vernon G. Wong
  • Phosphate-binding polymer preparation technical field
    Patent number: 6696087
    Abstract: A tablet containing a phosphate-binding polymer, which has an average particle size of 400 &mgr;m or less, contains particles of 500 &mgr;m or less in particle size at a ratio of 90% or more and has a moisture content of 1 to 14%, together with crystalline cellulose and/or low substituted hydroxypropylcellulose and contains the active component at a high ratio, is excellent in the ability to bind to phosphate, and quickly disintegrates in an acidic to a neutral region.
    Type: Grant
    Filed: March 6, 2002
    Date of Patent: February 24, 2004
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Katsuya Matsuda, Ryuji Kubota
  • Aqueous suspension with good redispersibility
    Patent number: 6683070
    Abstract: The aqueous suspension can be prepared by incorporating, in an aqueous suspension of a hardly soluble drug, a water-soluble polymer within the concentration range from the concentration at which the surface tension of the aqueous suspension of the drug begins to decrease up to the concentration at which the reduction in surface tension ceases. The resulting aqueous suspension shows ready redispersibility and will not undergo aggregation of dispersed particles or caking. Because of its good redispersibility, the suspension is useful as a parenteral preparation, eye drops, nasal drops, a preparation for oral administration, a lotion or the like.
    Type: Grant
    Filed: July 8, 2002
    Date of Patent: January 27, 2004
    Assignee: Senju Pharmaceutical Co., Ltd.
    Inventors: Shin-ichi Yasueda, Keiichi Matsuhisa, Hideo Terayama, Katsuhiro Inada
  • Method and composition for delivering zinc to the nasal membrane
    Patent number: 6673835
    Abstract: A viscous gel for delivering minor effective amounts of active substances through the nasal membrane into the body.
    Type: Grant
    Filed: September 1, 1999
    Date of Patent: January 6, 2004
    Assignee: Zicam LLC
    Inventors: Charles Hensley, Robert Steven Davidson
  • Bactericidal or bacteriostatic method
    Patent number: 6669903
    Abstract: Sterilization or bacteriostasis is carried out using cellulose acetate. The cellulose acetate exhibits an excellent antibacterial property with respect to fungi such as Trichophyton, etc. and bacteria such as, for example, enteropathogenic Escherichia coli O-157 or Methicillin tolerance Staphylococcus aureus. The cellulose acetate may be mixed with resin such as, for example, polyethylene or polypropylene, and this mixture may be used to produce fibers. Then, a textile product may be manufactured using the fibers thus produced. The cellulose acetate may be dissolved in a mixed solvent of ethyl acetate, ethanol, and methyl alcohol, so that a coating material is prepared. This coating material is applied to an object to be sterilized and then is dried to form a coating film made of cellulose acetate. This coating film exhibits the antibacterial property.
    Type: Grant
    Filed: June 1, 2001
    Date of Patent: December 30, 2003
    Assignees: Yokoyama Co., Ltd.
    Inventor: Michio Hayashi
  • Odor-masking coating for a pharmaceutical preparation
    Patent number: 6667059
    Abstract: A coating for masking or reducing the detectable presence of certain characteristic odor or odors, taste or tastes of pharmaceutical preparations, particularly Valerian extracts, is described. The coating comprises from one to three coating compartments, in any combination or as a single-layer amalgam. The first coating compartment comprises a hydroxyalkyl cellulose and an anti-tackiness agent. The second coating compartment may comprise a sugar and at least one anti-tackiness agent. The third coating compartment may comprise a methacrylate copolymer, a hydroxyalkyl cellulose and an anti-tackiness agent.
    Type: Grant
    Filed: May 30, 2001
    Date of Patent: December 23, 2003
    Assignee: Ancile Pharmaceuticals, Inc.
    Inventors: I-Lan T. Sue, Pou-Hsiung Wang, Lori McDonald Smith
  • Metformin hydrochloride tablets
    Patent number: 6667054
    Abstract: Tablets for oral administration comprising metformin hydrochloride and methylcellulose.
    Type: Grant
    Filed: December 5, 2001
    Date of Patent: December 23, 2003
    Inventor: Bernard Charles Sherman
  • Method of use of a biphasic controlled release delivery system for high solubility pharmaceuticals and method
    Patent number: 6660300
    Abstract: A biphasic controlled release delivery system for pharmaceuticals which have high water solubility, such as the antidiabetic metformin HCl salt, is provided which provides a dosage form that has prolonged gastric residence so that a dosing regimen of at least one gram metformin, once daily, may be achieved while providing effective control of plasma glucose.
    Type: Grant
    Filed: August 21, 2002
    Date of Patent: December 9, 2003
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Peter Timmins, Andrew B. Dennis, Kiren A. Vyas
  • Process for manufacturing coated granules with masked taste and immediate release of the active principle
    Patent number: 6660382
    Abstract: The invention concerns a method for making coated granules with masked taste and instant release of the active principle which consists in: first, mixing the constituents of a powder comprising at least the active principle and a granular disintegrating agent; then, granulating the resulting powder, in the presence of a mixture of carriers comprising at least a binding agent capable of binding the particles together to obtain grains; coating the grains formed by spraying a suspension comprising at least a coating agent and a membrane disintegrating agent; finally drying the resulting coated granules.
    Type: Grant
    Filed: January 8, 2002
    Date of Patent: December 9, 2003
    Assignee: Ethypharm
    Inventors: Noureddine Nouri, Jean-Marc Zuccarelli, Charles Chauveau, Etienne Bruna
  • Bleeding control and healing aid compositions and methods of use
    Patent number: 6652840
    Abstract: A composition is disclosed which has been shown to stop or control bleeding and seal open small blood vessels while accelerating the healing process of abraded oral “gum” and other “skin” (epithelial) tissues. The composition is preferably in the form of a paste which promotes ease of application and use of the composition. A variety of instruments can be used in application and cleanup of the composition showing versatile unparalleled friendly usage. The composition preferably comprises aluminum chloride, ferric sulfate (subsulfate), regenerated oxidized cellulose, aluminum ammonium sulfate, absorbable gelatin and a solvent. The composition has many dental and medical procedure applications.
    Type: Grant
    Filed: February 8, 2002
    Date of Patent: November 25, 2003
    Inventor: Terence Prevendar
  • Controlled release macrolide pharmaceutical formulations
    Patent number: 6642276
    Abstract: Disclosed is an oral controlled release macrolide pharmaceutical formulation. In a preferred embodiment, the formulation comprises a citrate salt of a preferred macrolide, clarithromycin. Also disclosed are methods for preparing, isolating and characterizing soluble and stable citrate salt of macrolides and use thereof in all solid dosage forms of macrolides.
    Type: Grant
    Filed: September 30, 2002
    Date of Patent: November 4, 2003
    Assignee: M/S Ind-Swift Limited
    Inventor: Hardeep Wadhwa
  • Modified release formulations containing a hypnotic agent
    Patent number: 6638535
    Abstract: Hypnotic pharmaceutical compositions are made from pellets and exhibit a modified release. Zolpidem or a pharmaceutically acceptable salt thereof is a typical hypnotic. The pellets are preferably spherical and exhibit a dissolution profile that includes 60% of the hypnotic agent being release from the pellet not earlier than 5 minutes from the start of a specified in vitro dissolution test. Although the modified release profile can include 50% of the hypnotic agent being released not earlier than 15 minutes after the start of the dissolution test, the pellet preferably does not contain a release rate controlling excipient or coating. Instead, microcrystalline cellulose and the active constitute the majority of the pellet, e.g. 90% or more. Spherical pellets are also made by a convenient method that is applicable to any pharmaceutically active agent.
    Type: Grant
    Filed: April 13, 2001
    Date of Patent: October 28, 2003
    Assignee: Synthon BV
    Inventors: Jacobus M. Lemmens, Dennie J. M. van den Heuvel, Johannes J. Platteeuw, Frans van Dalen
  • Hyaluronic acid gel composition, process for producing the same, and medical material containing the same
    Patent number: 6638538
    Abstract: A hyaluronic acid gel composition comprising hyaluronic acid and a polymer, which is substantially unmodified with a chemical cross-linking agent or a chemical modifying agent and which has a percentage dissolution of hyaluronic acid of 50% or lower in 12 hours in a neutral aqueous solution of 37° C.
    Type: Grant
    Filed: September 27, 2001
    Date of Patent: October 28, 2003
    Assignee: Denki Kagaku Kogyo Kabushiki Kaisha
    Inventors: Masamichi Hashimoto, Toshihiko Umeda, Kazuhiko Arai, Yoshiaki Miyata, Osamu Yamamoto, Yasukazu Himeda
  • Gastric retaining oral liquid dosage form
    Patent number: 6635281
    Abstract: The present invention is directed to an active agent dosage form which is adapted for retention in the stomach and useful for the prolonged delivery of a liquid, active agent formulation to a fluid environment of use. The liquid, active agent formulation is sorbed into porous particles that are dispersed in a polymer matrix that swells upon contact with the fluids of the stomach. A portion of the polymer matrix may be surrounded by a band of insoluble material that prevents the covered portion of the polymer matrix from swelling and provides a segment of the dosage form that is of sufficient rigidity to withstand the contractions of the stomach and delay expulsion of the dosage form from the stomach until substantially all of the active agent has been dispensed.
    Type: Grant
    Filed: December 22, 1999
    Date of Patent: October 21, 2003
    Assignee: Alza Corporation
    Inventors: Patrick S.-L. Wong, David E. Edgren
  • Oral suspension formulation
    Publication number: 20030191192
    Abstract: An aqueous pharmaceutical suspension for oral administration of a drug, which suspension maintains its content uniformity for prolonged period.
    Type: Application
    Filed: April 3, 2002
    Publication date: October 9, 2003
    Inventors: Danilo R. Venus, Eulogio C. Singh, Rita Josefina M. Santos, Ma. Joyce Bedelia B. Santos, Kennie U. Dee
  • Teat dipping agent
    Patent number: 6630458
    Abstract: Use of a composition comprising chitosan in combination with a polysaccharide selected from heparin, heparan sulphate and dextran sulphate, as an active component in a solvent, for the manufacture of a teat dipping solution for lactating animals, particularly cows. The invention also relates to a process for prophylactic or wound healing treatment of lactating animals, particularly cows, against mastitis.
    Type: Grant
    Filed: January 19, 1999
    Date of Patent: October 7, 2003
    Assignee: Medicarb AB
    Inventors: Olle Larm, Marcus Back
  • Compressed microparticles for dry injection
    Patent number: 6627600
    Abstract: The invention relates to a pharmaceutical implant for controllably releasing a drug in a subject and methods for manufacturing and administering the implant. The implant is made of associated microparticles of a drug dispersed in a biodegradable polymer. The microparticles are sufficiently associated so that the implant maintains a predetermined shape but are not fused together so as to form a single monolithic structure. The drug can be controllably released in a subject by administration of the pharmaceutical implant without the need of a suspending fluid.
    Type: Grant
    Filed: January 19, 2001
    Date of Patent: September 30, 2003
    Assignee: Ardana Bioscience Limited
    Inventor: Francois Boutignon
  • Low dose entecavir formulation and use
    Patent number: 6627224
    Abstract: Compositions containing a low dose of entecavir are administered on a daily basis to treat hepatitis B virus infection and/or co-infections. Formulations for the oral administration of a low dose of entecavir are provided. Other pharmaceutically active substances can be included in the entecavir composition or can be separately administered for the treatment of hepatitis B virus infection or for the treatment of co-infected patients.
    Type: Grant
    Filed: February 23, 2001
    Date of Patent: September 30, 2003
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Richard J. Colonno, Omar L. Sprockel, Abizer Harianawala, Divyakant Desai, Michael G. Fakes